Insider · CIK 0001736819
Christopher Horan
Files at ARTV (Artiva Biotherapeutics, Inc.). First filing Sep 4, 2026, latest Oct 6, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARTV: Artiva Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Artiva Biotherapeutics, Inc. | $71k 10,340 shares | -3% | +160% from low-47% from high | |
| 40Moderate | Artiva Biotherapeutics, Inc. | $116k 10,366 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | ARTV Artiva Biotherapeutics, Inc. | SOpen-market sale Common Stock | -10,340 | $6.84 | $71k | 312,744 | 6 d ago |
| Sep 9, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 323,084 | 31 d ago |
| Sep 9, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | 31 d ago |
| Sep 3, 2026 | ARTV Artiva Biotherapeutics, Inc. | SOpen-market sale Common Stock | -10,366 | $11.16 | $116k | 283,084 | 38 d ago |
| May 15, 2025 | ARTV Artiva Biotherapeutics, Inc. | FTax withholding Common Stock | -1,341 | $2.13 | $2,856 | 83,659 | Aug 18, 2025 |
| Aug 15, 2025 | ARTV Artiva Biotherapeutics, Inc. | FTax withholding Common Stock | -3,577 | $2.75 | $9,837 | 80,082 | Aug 18, 2025 |
| Feb 26, 2025 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 85,000 | Feb 28, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.